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Purpose: To identify mutations in the paired box 6 (PAX6) gene of 33 probands with aniridia and to reveal the mutational
spectrum in the Chinese population.
Methods: Unrelated probands with aniridia from 27 newly selected families and six previously analyzed families
participated in this study. The coding regions of PAX6 in the 27 new families were analyzed using cycle sequencing.
Families that lacked detectable variations based on sequencing (14 new and six previously analyzed) were further analyzed
using multiplex ligation-dependent probe amplification (MLPA).
Results: Fifteen mutations were identified in 16 of the 33 families: c.[65_94del30; 99_105dup7], c.101_102insA, c.
177delG, c.238_239insGCGA, c.1033–42_1033–26del17insG, c.1A>G, c.120C>A, c.718C>T, c.949C>T, c.1062C>A,
c.1183G>A, c.1268A>T, and three gross deletions involving exons 1–14, exons 8–14, and exons 9–14. The first five
mutations were novel and the c.1268A>T mutation was present in two families. Phenotypic variations were observed
between families and between different affected patients within the families.
Conclusions: The PAX6 mutation spectrum in Chinese aniridia patients is comparable to that reported in other ethnic
groups. Further studies of the 17 families with no detected mutations may provide additional information to improve the
understanding of the molecular genetics of aniridia.
Aniridia  (OMIM  106210)  is  a  bilateral,  panocular
disorder characterized by the absence of the iris. It is usually
accompanied by developmental defects of the cornea, lens,
retina, optic nerve, and/or the anterior chamber angle [1].
Approximately two thirds of all cases are transmitted as an
autosomal dominant trait among families. The remaining one
third are sporadic, with no family history [1-3]. Mutations in
PAX6 (OMIM 607108) have been shown to be responsible for
aniridia in most patients [4-10]. In rare cases, PAX6 mutations
may cause other ocular abnormalities, such as cataracts [11],
Peters anomaly [12,13], foveal dysplasia, microphthalmia,
and optic nerve malformations [14,15]. To date, at least 334
mutations in PAX6 have been identified [16]. However, the
absence of PAX6 mutations in some cases of aniridia implies
that mutations in additional genes cannot be excluded [6-10].
This possibility is supported by recent reports: 1) mutations
in the forkhead box C1 gene (FOXC1, OMIM 601090) are
associated with aniridia in two families [17,18] and 2) aniridia
in patients with preserved visual function are not related to
PAX6 mutations [19].
Understanding the mutation spectrum and frequency will
not only provide biomarkers for clinical practice but will also
represent a fundamental basis for identifying any additional
causative  genes.  The  spectrum  and  frequency  of  PAX6
mutations  in  Chinese  aniridia  patients  has  not  been  well
identified for the following reasons [20-27]: 1) most reports
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only involved a single or a limited number of families and 2)
mutations  were  usually  detected  by  cycle  sequencing
(detection of small variations), in which a larger deletion
involving part or all of the gene could not be detected. Cycle
sequencing  combined  with  multiplex  ligation-dependent
probe amplification (MLPA) has been shown to effectively
detect small mutations and large deletions in PAX6 [10]. In
this study, both cycle sequencing and MLPA were used to
detect mutations in the PAX6 gene of 33 Chinese probands
with aniridia.
METHODS
Patients:  Thirty-three  unrelated  probands  with  aniridia
participated in this study, including six families previously
analyzed by sequencing [22] and 27 newly selected families.
Patients  suspected  of  having  Peters  anomaly  or  Rieger
syndrome were excluded. All aniridia patients in this study
were recruited from our Pediatric and Genetic Eye Clinic at
the  Eye  Hospital  of  the  Zhongshan  Ophthalmic  Center,
Guangzhou, China. Written informed consent that complied
with the tenets of the Declaration of Helsinki and following
the  Guidance  of  Sample  Collection  of  Human  Genetic
Diseases (863-Plan) by China’s Ministry of Public Health was
obtained from each participant before the study. Genomic
DNA was prepared from venous blood.
Detection  of  PAX6  mutations:  Thirteen  pairs  of  primers
(Table 1) were used to amplify the 14 exons (3 noncoding
exons  and  11  coding  exons)  and  their  adjacent  intronic
sequences  of  PAX6  (NCBI  human  genome  build  37.2,
NC_000011.9  for  gDNA,  NM_001604.4  for  cDNA,  and
NP_001595.2 for protein). The PCR products of individual
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2139exons for each patient were sequenced using the ABI BigDye
Terminator  v3.1  Cycle  Sequencing  Kit  (ABI  Applied
Biosystems,  Foster  City,  CA)  and  the  ABI  3100  Genetic
Analyzer  (ABI  Applied  Biosystems)  according  to  the
manufacturer’s recommendations. Sequencing results from
patients’ sequences and PAX6 consensus sequences from the
National  Center  for  Biotechnology  Information  (NCBI)
human genome database (NC_000011.9) were imported into
the SeqManII program of the Lasergene package (DNAStar
Inc., Madison, WI) and aligned to identify variations. Each
mutation  was  confirmed  by  bidirectional  sequencing.
Mutation  descriptions  followed  the  nomenclature
recommended  by  the  Human  Genomic  Variation  Society
(HGVS) [28].
MLPA analysis: For patients who were determined not to have
a PAX6 mutation based on sequencing analysis, MLPA was
used to detect deletions of part or all of PAX6, according to
the manufacturer’s instructions (SALSA MLPA Kits P219-
B1 PAX6; MRC-Holland bv, Amsterdam, the Netherlands)
[10]. Briefly, 100 ng DNA samples were denatured for 5 min
at 98 °C and then cooled to 25 °C. Probes were mixed and
hybridized with DNA samples at 60 °C overnight and were
then reacted with ligase 65 at 54 °C for 15 min, followed by
5 min at 98 °C and then held at 4 °C. Finally, all probes and
sample  ligations  were  amplified  by  PCR  using  specific
carboxyfluorescein  (FAM)  labeled  PCR  primers.  PCR
products were separated by electrophoresis using the ABI
PRISM 3100 Analyzer. Data analysis was performed using
GeneMarker V1.5 software. A peak area between 0.7 and 1.3
times was considered normal; however, peak areas below 0.7
represent  deletions  and  those  above  1.3  represent
duplications.
RESULTS
Sequencing of the 14 exons of PAX6 of the 27 probands
revealed 12 mutations in 13 patients, including five novel
deletion/insertion  mutations  and  seven  known  point
mutations,  as  follows:  c.[65_94del30;  99_105dup7]
TABLE 1. PRIMERS USED FOR AMPLIFICATION AND SEQUENCING OF PAX6.
Primer ID Sequence (5′-3′) Product
length (bp)
Annealing
Temperature (°C)
Extra-E1-F* GAGCTGTGCCCAACTCTAGC    
Extra E1-R TCCATCTTTGTATGCCTCCTTT 399 56
Exon1F GGAGAGGGAGCATCCAATC    
Exon1R TCCTGGGAAGGAGACAGAGA 396 56
Exon2F ACACACTTGAGCCATCACCA    
Exon2R CTCCTGCGTGGAAACTTCTC 467 56
Exon3F AGAGAGCCCATGGACGTATG    
exon3R CCCAATCTGTTTCCCCTACA 318 56
Exon4F TGCAGCTGCCCGAGGATTA    
Exon4R GCACCCCGAGCCCGAAGTC 144 66
Exon5F TCCCTCTTCTTCCTCTTCACT    
Exon5R GGGGTCCATAATTAGCATC 301 61
Exon6–7F# GCTCTCTACAGTAAGTTCTC    
Exon6–7R AGGAGAGAGCATTGGGCTTA 457 61
Exon8F GATTTGCAGGTGTCATCAAT    
Exon8R ATATGGAGAGCTGCGTGGAT 212 65
Exon9F TTTGGTGAGGCTGTCGGGA    
Exon9R TCTTTGTACTGAAGATGTGGC 339 58
Exon10F GTAGTTCTGGCACAATATGG    
Exon10R GTACTCTGTACAAGCACCTC 206 62
Exon11–12F GGCTCGACGTAGACACAGT    
Exon11–12R TGCAGACACAGCCAATGAGG 500 62
Exon13F GCTGTGTGATGTGTTCCTCA    
Exon13R AAGAGAGATCGCCTCTGTG 245 62
Exon14F CATGTCTGTTTCTCAAAGGG    
Exon14R CCATAGTCACTGACTGAATTAACAC 202 61
        #Exon numbers are based on the current version of gene structure and NM_001604.4, where the original exon 5a is numbered
       as exon 6. *This extra exon is based on another transcript variant NM_001127612.1, which is not present in the trancript variant
       of NM_001604.4.
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2141(p.P22LfsX25),  c.101_102insA  (p.Q34fsx21),  c.177delG
(R59SfsX19),  c.238_239insGCGA  (p.S80fsx12),  c.1033–
42_1033–26del17insG  (splice  change),  c.1A>G  (Initiation
codon  abolished),  c.120C>A  (p.C40X),  c.718C>T
(p.R240X), c.949C>T (p.R317X), c.1062C>A (p.Y354X), c.
1183G>A (p.G395R), and c.1268A>T (p.X423LeuextX*15;
Table 2, Figure 1 and Figure 2). Of the 12 observed mutations,
eight resulted in a premature stop codon. The other four were
involved in the splicing acceptor, initial codon, or the stop
codon. No putative mutations were detected in the other 14
probands. No variants were detected in the three noncoding
exons (exons 1~3).
For the 20 probands in whom PAX6 mutations were not
detected by sequencing, including the remaining 14 probands
from this study and six probands from our previous study
[22], we detected PAX6 deletions involving multiple exons
(exons 1–14, 8–14, or 9–14, respectively) in three probands
detected by MLPA (Table 2, Figure 3).
Of  the  16  probands  with  PAX6  mutations,  all  had
congenital  nystagmus  and  foveal  dysplasia.  Complete
aniridia, subtotal aniridia, circumpupillary aplasia, or a full
iris in both eyes was recorded in probands 11, 2, 2, and 1,
respectively (Table 2). One proband (QT634) had a full iris,
but his father harbored the same heterozygous PAX6 mutation
and had complete aniridia. Additional ocular abnormalities
included  lens  opacities  (eight  probands),  inferior  corneal
leukoma  (one  proband  with  the  missense  mutation),  and
microcornea (one proband). The visual acuity of all probands
ranged from 0.1 to 0.3, except for five children who were too
young to be evaluated (Table 2). Phenotypic variations in the
family harboring the c.1A>G mutation were observed: one
proband (QT522) had complete absence of the iris in both
eyes, although her mother with the same PAX6 mutation only
had iris defects similar to iris coloboma (Figure 4). The patient
with  the  missense  mutation  (c.1183G>A,  p.G395R)  had
typical aniridia and inferior corneal leukoma.
DISCUSSION
The mutation frequency of PAX6 in Chinese aniridia patients
is similar to that in Caucasian aniridia patients. In this study,
PAX6 mutations were identified in 16 of the 33 families tested.
When the results of this study are combined with those of our
previous study [22], the PAX6 mutations have been identified
in 21 of 38 unrelated patients using cycle sequencing and
MLPA. Of the 21 patients, mutations in 18 patients were
identified by analyzing PAX6 coding regions using direct
sequencing, and mutations in 3 patients were detected using
MLPA. For PAX6 mutations in Chinese aniridia patients, the
overall  mutation  detection  rates  detected  with  cycle
sequencing, MLPA, or both were 47% (18/38), 8% (3/38), and
55% (21/38), respectively. In a similar study of Caucasian
aniridia patients [10], PAX6 mutations were detected in 49%
(34/70), 11% (8/70), and 60% (42/70) patients with cycle
sequencing,  MLPA,  or  both,  respectively.  Several  other
studies have detected aniridia-associated PAX6 mutations in
30% (9/30) of Mexican patients [29], 56% of Indian patients
[30], 67% (4/6) of Thai patients [31], 38%–58% (3/8–14/24)
of German patients [32,33], 50% (2/4) of Japanese patients
Figure 1. Frameshift mutations detected in PAX6. Five novel deletion/insertion mutations were identified in five probands with aniridia from
unrelated families. Pedigrees (left) are accompanied with sequence chromatography (right). Arrows indicate the probands. R represents reverse
sequence.
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2142Figure 2. Point mutations detected in PAX6. One missense and six nonsense mutations in PAX6 were found in eight probands with aniridia
from unrelated families. From left to the right, the columns represent pedigrees, sequencing results from probands with aniridia, and
corresponding sequences from normal controls.
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2143Figure 3. PAX6 mutations detected by MLPA. Three gross deletions were involved in exons 9–14, 8–14, and 1–14, respectively. Black arrows
indicate the exons with deletions, in which each peak area is below 0.7 compared to internal controls.
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2144[34], 79% (30/38) of Danish patients [35], and 83%–94%
(10/12–67/71)  of  British  patients  [9,36].  The  detection  of
these mutations was based solely on sequence analysis in most
studies,  but  chromosomal  analysis  was  additionally
performed in a few studies. These reports demonstrate that
while PAX6 mutations were prevalent, they were not detected
in all patients with aniridia. One reason that may account for
this is the possibility that small variations outside the exons,
such as intronic regions [10], may not be detectable by the
techniques  used  to  analyze  PAX6.  Furthermore,  frequent
chromosomal rearrangements have been described in aniridia
patients previously [37], which may not be detectable by cycle
sequencing  and  MLPA.  It  is  also  possible  that  there  are
mutations in other genes which contribute to aniridia given
that mutations in FOXC1 are associated with aniridia [17,18]
and that no PAX6 mutations were detected in aniridia patients
with preserved visual function [19].
The spectrum of PAX6 mutations in aniridia is similar
within  both  Chinese  and  Caucasian  patient  cohorts.  The
majority of PAX6 mutations reported so far would lead to
truncation of encoded proteins (such as nonsense, splicing,
insertion, or deletion mutation) and only about 2%–11.7% are
missense mutations [38,39]. In one review [38], 257 aniridia-
associated mutations were classified as nonsense mutations
(38.9%), splice mutations (13.2%), frame-shifting insertions
or deletions (25.3%), in-frame insertions or deletions (6.2%),
missense mutations (11.7%), and run-on mutations (4.7%).
For the 21 mutations in the Chinese patients analyzed in the
present study, these percentages are 33.3%, 14.3%, 19.0%,
zero, 9.5%, and 9.5%, with an additional 14.3% being gross
deletions of the PAX6 gene. In addition, seven point mutations
detected  in  this  study  are  known  mutations,  suggesting
common mutations. Of the seven, the p.R240X and p.R317X
mutations involving CpG dinucleotides are the most common
nonsense  mutations  in  PAX6.  The  p.C40X  mutation  was
detected in one patient in this study and another patient in our
previous study [22]. The run-on mutation, X423LeuextX*15,
was detected in two unrelated Chinese patients.
In this study, we detected five novel small insertion/
deletion mutations, seven known point mutations, and three
known gross deletions in 33 unrelated aniridia patients. In this
and one of our previous studies [22], the PAX6 gene was
analyzed by cycle sequencing and MLPA in 38 unrelated
aniridia  patients.  However,  PAX6  mutations  were  only
detected in 55% (21/38) patients. Further studies of the 17
families without PAX6 mutations may elucidate the molecular
basis of aniridia in these families.
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Figure 4. Photos showing the clinical phenotype of patients with a heterozygous c.1A>G mutation in PAX6. A and B: Complete absence of
iris and microcornea (9.5 mm in diameter) was observed in both eyes of the proband, an 18-year-old girl. C and D: A partial defect of the
bilateral iris mimicking iris coloboma was present in the proband’s mother, who also had the mutation. E and F: Foveal hypoplasia was
observed in the mother (E) and the proband (F). G and H: A flat fovea (G) and optic disc hypoplasia (H) in the mother were demonstrated
by optical coherence tomography and Heidelberg retinal tomography, respectively.
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